PHK
CNTA

Point72 Hong Kong’s Centessa Pharmaceuticals CNTA Stock Holding History

Point72 Hong Kong’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8
Closed – – 1985
2022
Q1 		$0 Buy
+8
New +$73 ﹤0.01% 1910

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Point72 Hong Kong's CNTA Position: Q2 2022 in Review

Point72 Hong Kong sold out of Centessa Pharmaceuticals (CNTA) in Q2 2022, closing a stake of 8 shares.

Point72 Hong Kong first reported a position in CNTA in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 41 funds tracked by Wall St. Rank hold CNTA as of Q2 2022.

  • Point72 Hong Kong reported no remaining Centessa Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 8 Centessa Pharmaceuticals shares in Q2 2022.
  • Point72 Hong Kong first reported a position in Centessa Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Point72 Hong Kong's Centessa Pharmaceuticals position peaked at $0 in Q1 2022.
  • 41 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.